By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Use. You can change your cookie settings through your browser.
I agree
Translating...
Content is automatically generated by Microsoft Azure Translator Text API. CGTN is not responsible for any of the translations.
TOP NEWS
Politics
07:00, 03-Mar-2025
Politics
11:22, 03-Mar-2025
Politics
14:20, 03-Mar-2025
Search Trends
SITEMAP
Copyright © 2024 CGTN. 京ICP备20000184号
Disinformation report hotline: 010-85061466
SITEMAP
Copyright © 2024 CGTN. 京ICP备20000184号
Disinformation report hotline: 010-85061466
CGTN anchor Zheng Junfeng interviewed AstraZeneca CEO Pascal Soriot, delving into the company's extensive strategic layout in China's pharmaceutical industry. From focusing on the domestic market to becoming a core base for global manufacturing and innovation, AstraZeneca has strengthened its business in China through significant investments in Wuxi and Qingdao, as well as a strong emphasis on research and development, contributing to the advancement of global health and economic growth.